| |
|
|
| |
|
|
 Issue
017 |
|
Phase
1 enhancement.
Xcelleron
Xceleron works alongside leading pharmaceutical
and biotechnology companies to meet the industry’s
most fundamental challenge: improving the efficiency
and cost-effectiveness of drug development. more... |
| |
|
|
| |
|
|
|
 Issue
015 |
|
A
new approach to finance
EuroBiO
Biotech companies work hard to find funding, however,
venture capitalists are becoming increasingly cautious.
The money is there, but to access it means a process
involving public tenders and industry partnerships.
EuroBiO 2009, the partnering and technology transfer
event for bioindustry, provides resources to help
companies change their approach. more...
|
| |
|
| |
Get
chirality right first time
Syncom
There are many technologies available for
the simultaneous screening of chiralities. Contract
research organisation Syncom offers an effective
and competitive service dedicated to early stage
drug development. more...
|
| |
Superior
gene silencing results
Life Technologies
Successful RNAi experiments depend on siRNAs.
The latest innovations in design, chemical modifications,
and off-target effect prediction algorithms have
been developed to produce the best performing siRNAs
in the industry. more...
|
| |
siRNA
delivery into primary neuronal cells
Thermo Scientific
Functional studies in primary neurons have
proved that a novel, highly effective method can
now be used to deliver siRNA without a transfection
reagent. A straightforward protocol and a growing
list of cell-type specific tips will increase success,
even in difficult cell types. more...
|
| |
|
| |
Differential
anchorage probes
Fluofarma
Cellular proteases play a fundamental role in many
cellular processes and are intimately involved in
the development of many diseases, thus representing
valuable targets for therapeutic intervention. Biochemical
assays using peptide-conjugated substrates are widely
used for characterising proteases. more...
|
| |
|
| |
Ion
channel targets
Genionics AG
Genionics AG is a privately funded Swiss Biotech
company, established in 2007 at the Biotech Centre
Zurich. The company is dedicated to the genetic
diversity of ion channels and is in the process
of building and marketing a comprehensive catalogue
of ready-to-use ion channel targets. more...
|
| |
Saving
through profiling
Reaction Biology Corp
The high cost of compound profiling has restricted
its optimum use in early stage drug discovery, which
means that companies typically develop lead candidates
with SAR and toxicity testing, and only then profile
the few resulting compounds for selectivity. A negative
result can mean many months of wasted time. more...
|
|
 Issue
014 |
|
A
unique drug development partner
Quotient Bioresearch
Focused on science, technology and
people, Quotient Bioresearch is dedicated
to providing the best service and high quality
data to help its clients make the right decisions.
more...
|
| |
|
| |
Perfect
powder dosing
Mettler Toledo
Spatulas will soon be a thing of the past for
weighing in small and critical samples. METTLER
TOLEDO, the global producer of precision instruments,
has developed QUANTOS as the first system that
automatically doses even the smallest powder quantities.
more...
|
|
 Issue
013 |
|
A
‘fail-early’ approach to compound screening
Genetix
A large number of compound failures in
the drug discovery process are due to toxicity.
The strategy within the industry is to identify
these compounds as early as possible to reduce the
time and costs it takes to bring a drug to market.
more... |
| |
|
| |
Revolutionary
pipette
flyion GmbH
Patch clamp is used to study individual ion channels
in cells, but its manual application is time-consuming
and complicated. A uniqque approach has been developed
that enables the patch clamp experiment to be performed
inside a glass pipette. more... |
|
 Issue
012 |
|
A
fast key for slow gatekeepers
IonGate Biosciences GmbH
Wolfgang Lerch, CEO of Iongate Biosciences,
reports on an exciting technological development,
in use for just over a year, which accesses the
transporters using cell-free electrophysiology.
more.. |
| |
|
| |
Utilization
of cell-based assays
Genetix
The time and costs of drug discovery have
increased over the past twenty years. Thus, it is
of paramount importance that the selection and concomitant
dismissal of compounds is achieved earlier in the
drug discovery process. The utilization of cell-based
assays in primary screening, secondary screening
and ADMET (adsorption, distribution, metabolicity,
excretion and toxicity) facilitates the selection
of compounds that have favourable biological properties.
more... |
| |
|
| |
A
new era for RNAi
Thermo Fisher Scientific
For five years the potential of RNA-interference
technology to improve the drug discovery and development
process has been a hot topic. Turning the principle
into a practical technology platform may not have
been simple, but recent studies have shown that
the hype about RNAi may be justified. more.. |
|
 Issue
010 |
|
Biomarkers:
the next step
Gene Logic
Biomarkers are measured and evaluated as
indicators of biological or pathogenic processes,
or of pharmacological or toxicological responses.
They include secreted proteins, as well as DNA and
expression markers. Biomarkers hold the key to improving
our understanding of the underlying biological triggers
driving these processes. more.. |
| |
|
| |
Dream in blue
Provence Technologies
Group
Methylene blue is finally available in a safe,
stable format without heavy-metal contamination,
all thanks to a four-year R&D commitment from
Provence Technologies. more.. |
| |
|
| |
Preclinical
drug development
Evotec (Scotland)
Ltd
Clinical trials can be extremely complex,
which is why the adoption of a smooth development
process is crucial in taking a drug successfully
from the cleanroom to final medicine status, writes
Dr Alan Baillie, technical director for Evotec (Scotland)
Ltd. more.. |
| |
|
| |
Taking
Hts To The Next Level
Greiner
High-throughput screening has enabled pharmaceutical
companies to run assays on more compounds than ever
before, but there has been no appreciable increase
in the number of final drugs approved for sale.
Some technology developers feel that this is because
screening has focused on quantity rather than quality.
more.. |
| |
|
| |
Harnessing
the power of RNAI
Ambion
RNAi has become a useful tool in target identification
and validation. It provides critical functional
data about alleged drug targets that is proving
invaluable in drug discovery pipelines. more.. |
|
 Issue
009 |
|
High-throughput
calcium mobilisation
Chemicon International, Inc
A novel method of receptor expression and G-protein
coupling has created a reliable and universal calcium
mobilisation assay platform for all GPCRs. more.. |
|
 Issue
008 |
|
The
importance of molecular structure
Chemical Computing Group
Crystallographic techniques provide huge amounts
of information about molecular structures. This
information is stored in the Cambridge Structural
Database and the Protein Data Bank, and both have
proved invaluable to drug discovery researchers.
more... |
| |
|
| |
Genomic
drug development
Gene Logic Inc.
Scientists worldwide know Gene
Logic for compiling the largest and most detailed
proprietary knowledgebase of gene expression profiles
of human and animal tissues and cells. more.. |
| |
|
| |
Related
articles from this issue |
| |
|
| |
 The
emergence of virtual screening
High throughput screening of large collections
of chemical compounds remains an important step
in many drug discovery research projects. Jin Li
and Timothy Lovell, Chemical Computing, AstraZeneca,
review the complementary virtual screening methodologies.
|
| |
|
| |
Is
there a mux up?
Nicholas Westwood, University of St
Andrews, and Graham Smith, Pfizer Global
R&D, discuss the technology associated
with the analysis of crude reaction mixtures. |
|
 Issue
007 |
|
The
power of in situ proteomics
MelTec GmbH &
Co
MelTec GmbH & Co, KG, is a privately
held company that harnesses proprietary topological
proteomics technologies to enhance and facilitate
the discovery and development of new drugs for a
wide range of therapeutic areas... more.. |
| |
|
| |
R&D
drives future growth
Invitrogen Corporation
Invitrogen Corporation
provides products and services that support academic
and government research institutions and pharmaceutical
and biotech companies worldwide in their efforts
to improve the human condition... more.. |
| |
|
| |
Novel
instrumentation for high quality/high content screening
MAIA SCIENTIFIC
MAIA SCIENTIFIC, a wholly-owned subsidiary
of Harvard Bioscience, develops, manufactures and
markets novel instrumentation and applications for
high quality/high content screening... more.. |
| |
|
| |
MicroRNA:
Small regulators with global impact
Ambion
MicroRNAs (miRNAs) are an important
class of small RNA molecules that are expressed
in eukaryotes... more.. |
|
 Issue
006 |
|
Develop
new medicines safer and faster
Inte:Ligand
The business concept behind Inte:Ligand is a simple
one: to speed up and make the drug development process
safer. more.. |
| |
|
| |
Related
articles from this issue |
| |
|
| |
RNA
silencing speaks for itself
Technology for RNA silencing has matured rapidly.
Dr Thomas Tuschl, associate
professor at Rockefeller University, tells World
Pharmaceutical Frontiers that its
potential is becoming clearer and predicts investment
in its future.
|
